Save the Date for BioTrinity 2012 - European Biopartnering and Investment Conference - April 24 -26 


Add to Outlook Calendar Add to Outlook Calendar       Follow BioTrinity on Twitter Follow BioTrinity on Twitter

Where Great Minds and Smart Money Meet Under One Roof

View Photos from the BioTrinity 2011 Gallery BioTrinity is the premier European Biopartnering and Investment Conference, where great minds and smart money meet under one roof. BioTrinity partners R&D companies and big pharma with more biomedical investors than any other European partnering conference. BioTrinity's company showcase profiles assets at all stages of development from discovery, preclinical, phase I to phase II as well as phase III, rather than marketed products. Register Now

 Meet a hand-picked crop of early-stage companies you haven't seen elsewhere

 Meet 100 delegates from active VC and Corporate Venture firms

 Meet the key licensing contacts from big pharma

 Meet the senior execs who can complete the value chain for your business

...Deploying EBD Group's partneringONE®, the industry gold-standard partnering system with entirely private partnering: 

partneringOne

BioTrinity 2011 emerged as the UK's largest partnering event:

Find out more about BioTrinity's emergence as the largest biopartnering event in the UK, or read about discussions on financing opportunities discussed at BioTrinity 2011.

BioTrinity 2012 will again be the Largest Gathering of the UK's Bioindustry (Apr 24-26), and is Europe's Fastest Growing Biopartnering and Investment Conference, facilitating more meetings with more investors than any other UK conference. BioTrinity 2012 will feature a showcase of the best of the UK and Europe's emerging and clinical stage companies, reflecting the growing level of participation from European biotechs. Big pharma and their corporate venturers participating in 2012 included Novartis, AstraZeneca, Shire, Merck, GSK, Pfizer, Sanofi Aventis, Boehringer, Baxter, Takeda, Teva, Lilly, Abbott, Smith & Nephew, Fosun Pharma, Ironwood Pharma, Merck Serono, Novo A/S and Lundbeckfund. You can partner with the best at BioTrinity. Register Now to ensure you don't miss out!

You need to upgrade your Flash Player


The "Event of the Year" - BioTrinity 2012:

Huge partnering potential with global pharma / investors

 60 presentations by hand-picked R&D companies

Great networking opportunities

 First class venue at Newbury Racecourse

Exciting Social Programme:

 Grand Opening Reception and Gala Dinner

 Europe's Largest Investor-only Dinner

Projected 2012 Statistics:

 850+ delegates

 2500 formal one-to-one partnering meetings

 100 investment firms from 12 countries

 All of the top 20 global pharma

2011 Statistics:

 750+ delegates (up 21%) from 20 countries

 1700 partnering meetings (up 20%)

 75 investment firms from 12 countries

 Nearly all of the top 20 global pharma


Given its prodigious year-on-year growth, and doubling in size in three years, we believe BioTrinity 2012 will be the biggest and best yet: 850 plus delegates, over 2500 partnering meetings (up 50% again on the previous year), 100 delegates from investment firms and licensing representation from the key global pharma companies.  Remember BioTrinity is the only bioconference in Europe to have grown over 100% over three years of recession - read the testimonials to find out why people are flocking to BioTrinity.

Check out the glowing testimonials we received for BioTrinity, and view the photos from the Gallery or watch the video now.